Mackie Research Capital analyst Andre Uddin downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter